HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senior Attorney: NAD Fills Regulatory “Void” In Setting Ad Standards

This article was originally published in The Rose Sheet

Executive Summary

NAD decisions reference FDA and Federal Trade Commission regulations, but go a distance on their own to establish standards for advertising claims, senior attorney Kathleen Dunnigan suggests. “What we really do is we fill a void, which is to set advertising standards and to try to get truthful and accurate claims,” she says at FDLI’s annual conference.

You may also be interested in...

Regulatory Action Is Lesser Of Firms’ Worries Amid Class-Action Blitz

Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years in today’s litigious climate, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics in New York. Speakers provided examples and tips for staying out of court.

J&J Fights NAD Neutrogena Decision Assailing Sunscreen “Barrier”

In a challenge brought by Coppertone sunscreen products marketer Merck & Co., NAD reviews claims for Neutrogena in print, online and in-store advertising, as well as on packaging for Neutrogena Beach Defense lotion and spray. J&J argues its claim uses same term as FDA’s online “Sun Protection” page.

GSK Leaving Pennsylvania Emergen-C Plant, Adding Voltaren To US OTC Line

UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts